Multiple Myeloma Diagnostics Market

Multiple Myeloma Diagnostics Market: Global Industry Analysis 2014-2018 and Opportunity Assessment 2019 - 2029

  • Ongoing
  • May 2020
  • REP-GB-9930
  • PDF PPT EXCEL
Multiple Myeloma Diagnostics Market
  • SELECT LICENSE TYPE :

  • US$5,000
  • US$7,500
  • US$10,000

This Multiple Myeloma Diagnostics market study offers a comprehensive analysis of the business models, key strategies, and respective market shares of some of the most prominent players in this landscape. Along with an in-depth commentary on the key influencing factors, market statistics in terms of revenues, segment-wise data, region-wise data, and country-wise data are offered in the full study. This study is one of the most comprehensive documentation that captures all the facets of the evolving Multiple Myeloma Diagnostics market.


Multiple Myeloma Diagnostics: Market Insights

Plasma cells help in fighting infection however, malignant plasma cells in multiple myeloma accumulate in the bone marrow, blocks the normal function of plasma cells. The M protein which is an abnormal antibody produced by malignant plasma cells cause tumors, bone destruction, kidney damage, and damaged immune function. However, in the recent years, ten new drugs have received in approval in short period of time due to the formation of Multiple Myeloma Research Foundation and the increasing attention, advancement, and researches for multiple myeloma diagnostics and therapies. These factors contributing to the growth of multiple myeloma diagnostics market. Moreover, increasing funding for the research and development and rising clinical trials is expected to provide the most promising multiple myeloma treatments options and will boost the growth of multiple myeloma diagnostics market.

Market Growth Analysis

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

COVID -19 : Impact Analysis

Request the coronavirus imapact analysis across industries and markets

Request Covid -19 Impact

Multiple Myeloma Diagnostics: Market Insights

Plasma cells help in fighting infection however, malignant plasma cells in multiple myeloma accumulate in the bone marrow, blocks the normal function of plasma cells. The M protein which is an abnormal antibody produced by malignant plasma cells cause tumors, bone destruction, kidney damage, and damaged immune function. However, in the recent years, ten new drugs have received in approval in short period of time due to the formation of Multiple Myeloma Research Foundation and the increasing attention, advancement, and researches for multiple myeloma diagnostics and therapies. These factors contributing to the growth of multiple myeloma diagnostics market. Moreover, increasing funding for the research and development and rising clinical trials is expected to provide the most promising multiple myeloma treatments options and will boost the growth of multiple myeloma diagnostics market.

Multiple Myeloma Diagnostics: Overview

Technological advancement and rising clinical studies for the management of multiple myeloma are the main factor to boost the market growth of multiple myeloma diagnostics market. Additionally, rising disposable income is expected to boost the growth of multiple myeloma diagnostics market. However, lack of awareness and expertise can lead to complications and can damaged the immune function of the heart which may lead to the heart failure. The poor management of multiple myeloma may lead to restraint the growth of multiple myeloma diagnostics market.

Multiple Myeloma Diagnostics: Region-wise Outlook

The Asia-Pacific multiple myeloma diagnostics market is expected to show fast growth due to rising heart-related problems and lack of awareness regarding the management of multiple myeloma. The multiple myeloma diagnostics market is expected to be dominated by North America due to advanced healthcare infrastructure and reimbursement in the region. Latin America Multiple myeloma diagnostics market is expected to experience steady growth due to lack of expertise in the region. Europe is expected to score second place in the multiple myeloma diagnostics market due to availability of skilled healthcare professionals coupled with higher adoption in the region. The Middle East & Africa is expected to be the least lucrative multiple myeloma diagnostics market due to least product availability and lack of facilities in the region.

Multiple Myeloma Diagnostics: Key Players

Some of the key players present in global multiple myeloma diagnostics market are Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Genzyme Corporation, Celgene Corporation, Millennium Pharmaceuticals, Novartis AG, Amgen, Inc., Juno Therapeutics, Janssen Biotech, Inc., Johnson & Johnson, GlaxoSmithKline plc, Pfizer, AbbVie Inc., Innate Pharma SA, Onyx Pharmaceuticals, Celldex Therapeutics, Inc., and Takeda Pharmaceuticals.

The report covers exhaustive analysis on:

  • Multiple Myeloma Diagnostics Market Segments
  • Multiple Myeloma Diagnostics Market Dynamics
  • Multiple Myeloma Diagnostics Market Size
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Multiple Myeloma Diagnostics Value Chain

The regional analysis includes:

  • North America (U.S., Canada)
  • Latin America (Mexico, Brazil, Rest of Latin America)
  • Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX, Russia, Rest of Europe)
  • East Asia (China, Japan, South Korea)
  • South Asia (India, Indonesia, Malaysia, Rest of East Asia)
  • Middle East and Africa (N. Africa, S. Africa, Israel, Rest Of MEA)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Unique Requirements? Customize this Report

  • Customize by Region, Country, Application, Product, & other segments
  • Integrate our Insights with your Existing Data
  • Determine the scope of the study to suit your requirements

Let FMI Help You!

  • Gain Insights on Key Multiple Myeloma Diagnostics Market Impacting Forces
  • Know the Winning Strategies of Market Leaders
  • Get Deep-Dive Analysis on Each Segment
  • Identify the Sources that will Drive Top-Line Revenue

Multiple Myeloma Diagnostics: Segmentation

The global Multiple Myeloma Diagnostics market is segmented by drug type, end user, and regions:

Multiple Myeloma Diagnostics Segmentation by Drug Type

  • Proteasome Inhibitors
  • Velcade (bortezomib)
  • Kyprolis® (carfilzomib)
  • Ninlaro® (ixazomib)
  • Immunomodulatory Agents (IMiDs)
  • Thalomid® (thalidomide)
  • Revlimid® (lenalidomide)
  • Pomalyst® (pomalidomide)
  • Histone Deacetylase (HDAC) inhibitors
  • Farydak® (panobinostat)
  • Immunotherapy
  • Darzalex™ (daratumumab)
  • Empliciti® (elotuzumab)
  • Cytotoxic Chemotherapy
  • Doxil

Multiple Myeloma Diagnostics Segmentation by Distribution Channel

  • Institutional Sales
  • Hospital Pharmacies
  • Specialty Clinic
  • Retail Sales
  • Drug Stores
  • Retail Pharmacies
  • Online Pharmacies

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
Frequently Asked Questions

Why choose FMI?
  • With a global presence and a trusted partner to several Fortune 500 firms, FMI covers 1 billion+ data points to build a diversified portfolio for market benchmarking
  • Market Reports researched and peer reviewed by industry experts from across the globe
  • We follow a multi-dimensional method of analysis monitoring a three-layer data validation process
  • In addition to demand-side market assessment, our data triangulation methodology involves supply-side research
  • Primary research includes mandatory field interviews with stakeholders involved
  • Customizing reports according to client specification is also our forte
  • The current and future market size, covering each aspect and nuanced trends across key national and geographic markets
  • An overview of the market report, providing an imperative visual of the varied market subdivisions and overall forecast statistics in terms of value and volume
  • Extensive database and key dynamics elevating the market with varied verticals associated
  • Underlying Multiple Myeloma Diagnostics Market forces that are compelling consumers or businesses to purchase the product
  • How novel technologies and consumer-centric innovations will create new value-adding opportunities for companies active in the Multiple Myeloma Diagnostics Market
  • What will be environment and regulatory impacts on the market over the next decade
  • Investment Feasibility Matrix - It shows returns on investment, level of competition, success rate of investment, and potential risks associated with the market. The analysis shows that the competition is high in the established market, while the returns for short-term investment are also taken into consideration
  • Relative Maturity Mapping – The relative maturity is measured according to three growth phases (growth, maturity, decline)
  • Relative PLC (Product Life Cycle) – Analysis of the emergence of prominent players and competitive test prices which are driving factors behind every market. (expected market behavior, observed market behavior, expected market performance, observed market performance)
Get in touch
Harish Tiwari

Harish Tiwari

Global Head - Business Development

* indicates mandatory fields
Our Clients

Request Sample Request customization Request Methodology